Cevostamab, RoActemra 20 mg/mL concentrate for solution for infusion
CO43476
Phase 2 small_molecule active
Quick answer
Cevostamab, RoActemra 20 mg/mL concentrate for solution for infusion for Relapsed/Refractory Multiple Myeloma is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active